Detailed results from Biogen Idec and AbbVie's pivotal Phase 3 DECIDE study further define the efficacy and safety profile of ZINBRYTA™ (daclizumab high-yield process)
Biogen Idec, 12 Sep 2014
Accessed on 15 Sep 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2377&M=NewsV2&PID=61997.